Semafore’s PI3 Kinase Inhibitor SF1126 Is Active Against Tumor And Tumor Cells And Synergizes With Standard Chemotherapy Agents
Oct 28th 2007Drug InformationCancer
Semafore Pharmaceuticals Inc. announced on the occasion of a poster presentation at the 2007 AACR-NCI- EORTC International Conference in San Francisco that its integrin-targeted PI3 kinase inhibitor, SF1126, showed synergistic effects with certain standard chemotherapy agents in vitro and in vivo (poster C207). In vitro data showed significant (p [click link for full article]
More: continued here
No Comments »
Leave a Reply
You must be logged in to post a comment.
